Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials
Phase meta-analysisN = 6,633
- Population
- Patients with multiple myeloma in 27 randomised trials of combination chemotherapy versus melphalan plus prednisone.
- Design
- Collaborative overview of randomised trials of combination chemotherapy versus melphalan plus prednisone: individual patient data on 4,930 patients from 20 trials, plus published data on a further 1,703 patients from seven trials. The main outcome measure was mortality; response and recurrence rates were subsidiary end points.
- Arms
- Combination chemotherapy (experimental): Combination chemotherapy regimens as tested in the pooled trials
- Melphalan plus prednisone (control): Melphalan plus prednisone
- People
- Myeloma Trialists' Collaborative Group, Myeloma Trialists' Collaborative Group
Δ ORR+6.8 points
Show the numbers
| Endpoint | Analysis | Combination chemotherapy | Melphalan plus prednisone | Effect |
|---|---|---|---|---|
| ORRAll trials taken togetherResponse rate as defined by the individual trials (not specified in the abstract). | primaryMyeloma 1998 | 60% | 53.2% | P<0.00001Mortality, the main outcome, showed no evidence of a difference: a nonsignificant 1.5% reduction in death rate in favour of combination chemotherapy (P=0.6, two-tailed). |
| Endpoint | Analysis | Combination chemotherapy | Melphalan plus prednisone | Effect |
|---|---|---|---|---|
| ORRAll trials taken togetherResponse rate as defined by the individual trials (not specified in the abstract). | primaryMyeloma 1998 | 60% | 53.2% | P<0.00001Mortality, the main outcome, showed no evidence of a difference: a nonsignificant 1.5% reduction in death rate in favour of combination chemotherapy (P=0.6, two-tailed). |